HomeCompareWTBFA vs ABBV

WTBFA vs ABBV: Dividend Comparison 2026

WTBFA yields 0.97% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $77.2K in total portfolio value
10 years
WTBFA
WTBFA
● Live price
0.97%
Share price
$575.00
Annual div
$5.55
5Y div CAGR
25%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.2K
Annual income
$1,100.13
Full WTBFA calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — WTBFA vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodWTBFAABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, WTBFA + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
WTBFA pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

WTBFA
Annual income on $10K today (after 15% tax)
$82.04/yr
After 10yr DRIP, annual income (after tax)
$935.11/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $20,120.89/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of WTBFA + ABBV for your $10,000?

WTBFA: 50%ABBV: 50%
100% ABBV50/50100% WTBFA
Portfolio after 10yr
$63.8K
Annual income
$12,935.94/yr
Blended yield
20.29%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

WTBFA
No analyst data
Altman Z
0.3
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

WTBFA buys
0
ABBV buys
0
No recent congressional trades found for WTBFA or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricWTBFAABBV
Forward yield0.97%3.06%
Annual dividend / share$5.55$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR25%40.6%
Portfolio after 10y$25.2K$102.3K
Annual income after 10y$1,100.13$24,771.77
Total dividends collected$4.5K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: WTBFA vs ABBV ($10,000, DRIP)

YearWTBFA PortfolioWTBFA Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,821$120.65$11,550$430.00$729.00ABBV
2$11,731$152.52$13,472$627.96$1.7KABBV
3$12,745$193.16$15,906$926.08$3.2KABBV
4$13,882$245.16$19,071$1,382.55$5.2KABBV
5$15,166$311.96$23,302$2,095.81$8.1KABBV
6$16,626$398.14$29,150$3,237.93$12.5KABBV
7$18,299$509.88$37,536$5,121.41$19.2KABBV
8$20,236$655.62$50,079$8,338.38$29.8KABBV
9$22,499$846.97$69,753$14,065.80$47.3KABBV
10$25,175$1,100.13$102,337$24,771.77$77.2KABBV

WTBFA vs ABBV: Complete Analysis 2026

WTBFAStock

W.T.B. Financial Corporation operates as the bank holding company for Washington Trust Bank that provides banking, fiduciary, asset management, mortgage banking, and other financial services to corporate and individual customers. The company's deposit products include checking, savings and money market, health savings, individual retirement, and analyzed accounts, as well as certificates of deposit. It also offers credit and debit cards; home, auto, boat, motorcycle, motor home, home equity, equipment, debt refinancing, term, and agriculture loans; and SBA and commercial real estate financing products, as well as revolving, personal, and home equity lines of credit. In addition, the company provides investment products and services, such as retirement planning, mutual funds, stocks/bonds, life/long-term care insurance, annuities, brokerage, planning, and education funding. Further, it offers wealth management services consisting of investment management, charitable and nonprofit administration, estate settlement, family office, trust administration, retirement planning, employee benefits administration, and custody services, as well as portfolio management services. Additionally, the company provides digital wallets; remote deposit, merchant, treasury management, private banking, and online and mobile banking services; and documentary and standby letters of credit, documentary collection, foreign exchange products, foreign accounts receivable insurance, and SBA export loan guaranty programs. It operates through 42 branches and offices in Washington, Idaho, and Oregon. The company was founded in 1902 and is headquartered in Spokane, Washington.

Full WTBFA Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this WTBFA vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

WTBFA vs SCHDWTBFA vs JEPIWTBFA vs OWTBFA vs KOWTBFA vs MAINWTBFA vs JNJWTBFA vs MRKWTBFA vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.